Correlation Between Cue Biopharma and Compass Therapeutics
Can any of the company-specific risk be diversified away by investing in both Cue Biopharma and Compass Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cue Biopharma and Compass Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Cue Biopharma and Compass Therapeutics, you can compare the effects of market volatilities on Cue Biopharma and Compass Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cue Biopharma with a short position of Compass Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cue Biopharma and Compass Therapeutics.
Diversification Opportunities for Cue Biopharma and Compass Therapeutics
0.3 | Correlation Coefficient |
Weak diversification
The 3 months correlation between Cue and Compass is 0.3. Overlapping area represents the amount of risk that can be diversified away by holding Cue Biopharma and Compass Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Compass Therapeutics and Cue Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cue Biopharma are associated (or correlated) with Compass Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Compass Therapeutics has no effect on the direction of Cue Biopharma i.e., Cue Biopharma and Compass Therapeutics go up and down completely randomly.
Pair Corralation between Cue Biopharma and Compass Therapeutics
Considering the 90-day investment horizon Cue Biopharma is expected to under-perform the Compass Therapeutics. In addition to that, Cue Biopharma is 1.53 times more volatile than Compass Therapeutics. It trades about -0.01 of its total potential returns per unit of risk. Compass Therapeutics is currently generating about 0.02 per unit of volatility. If you would invest 173.00 in Compass Therapeutics on September 2, 2024 and sell it today you would lose (10.00) from holding Compass Therapeutics or give up 5.78% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Cue Biopharma vs. Compass Therapeutics
Performance |
| Timeline |
| Cue Biopharma |
| Compass Therapeutics |
Cue Biopharma and Compass Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Cue Biopharma and Compass Therapeutics
The main advantage of trading using opposite Cue Biopharma and Compass Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cue Biopharma position performs unexpectedly, Compass Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Compass Therapeutics will offset losses from the drop in Compass Therapeutics' long position.| Cue Biopharma vs. Coya Therapeutics, Common | Cue Biopharma vs. Lantern Pharma | Cue Biopharma vs. Fennec Pharmaceuticals | Cue Biopharma vs. Eliem Therapeutics |
| Compass Therapeutics vs. Ideaya Biosciences | Compass Therapeutics vs. AnaptysBio | Compass Therapeutics vs. MeiraGTx Holdings PLC | Compass Therapeutics vs. Keros Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Complementary Tools
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Transaction History View history of all your transactions and understand their impact on performance |